Research and development expenditure
First written in FY2023-Q3. 7 of 13 entries say "Restated". Latest entry: FY2027-H1.
1 other company's latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「The amount spent on research and development activities during the interim accounting period was ¥302.980 million. There were no material changes in the status of the company’s research and development activities during the interim accounting period.」
The company continued its research and development activities, with research and development expenses increasing from ¥239.516 million in the same period of the previous year to ¥302.980 million. - FY2026Decline in R&D ExpensesAnnual report
「Total research and development expenses for the fiscal year were ¥493.884 million.」
Research and development activities are continuing, but research and development expenses decreased from ¥539.836 million in the previous fiscal year to ¥493.884 million. - FY2026-H1RestatedAnnual report
「Research and development expenditure for the six months ended the interim period was ¥239.516 million. There were no material changes in the status of the company's research and development activities during the interim accounting period.」
The company continues its research and development activities and has disclosed expenditure for the interim accounting period. The disclosure states that there were no material changes in the status of those activities. - FY2025AdvancedAnnual report
「The company had 42 research and development personnel during the fiscal year, and total research and development expenses were ¥539.836 million.」
The company had 42 research and development personnel, and research and development expenses were ¥539.836 million, representing an increase in scale from 27 personnel and ¥296.702 million in the previous fiscal year. - FY2025-H1RestatedAnnual report
「Research and development expenditure for the six months ended the interim period was ¥297.126 million. There were no material changes in the status of the company's research and development activities during the interim accounting period.」
The company continues its research and development activities and has disclosed expenditure for the interim accounting period. The disclosure states that there were no material changes in the status of those activities. - FY2025-Q1RestatedAnnual report
「Research and development expenditure for the three months ended the first quarter was ¥162.376 million.」
The company continues its research and development activities and has disclosed expenditure for the three months ended the first quarter. - FY2024-Q3RestatedAnnual report
「Research and development expenditure for the nine months ended the third quarter was ¥405.037 million.」
The disclosure reports research and development expenditure for the nine months ended the third quarter and states that research and development activities are continuing. - FY2024-Q2RestatedAnnual report
「Research and development expenditure for the six months ended the second quarter was ¥253.974 million.」
The disclosure reports research and development expenditure for the six months ended the second quarter. - FY2024-Q1RestatedAnnual report
「Research and development expenditure for the three months ended the first quarter was ¥130.292 million.」
The disclosure reports research and development expenditure for the first quarter. - FY2023AdvancedAnnual report
「The company had 27 research and development personnel during the fiscal year, and total research and development expenses were ¥296.702 million.」
The company had 27 research and development personnel, and research and development expenses were ¥296.702 million, an increase from the expenditure reported in the previous filing. - FY2023-Q3First statedAnnual report
「Research and development expenditure for the nine months ended the third quarter was ¥185.335 million.」
The disclosure reports research and development expenditure for the period.